Author

Fiona Donovan

Observed name: F Donovan

Institution: St George’s University Hospitals NHS Foundation Trust

Observed institutions: St George's Hospital, St George's, University of London, St George’s University Hospitals NHS Foundation Trust, City St George's, University of London

ORCID: 0009-0007-1897-9842

Observed ORCID: 0009-0007-1897-9842

OpenAlex ID: A5005713409

JAK inhibitors for inflammatory bowel disease: recent advances

2023 · Sailish Honap, Alexandra Agorogianni, et al. · Frontline Gastroenterology · 143

Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy ( IMSAT ) therapeutic drug monitoring study

2022 · Neil Chanchlani, Simeng Lin, et al. · Alimentary Pharmacology & Therapeutics · 22

Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center

2025 · Michael Colwill, Jessica Padley, et al. · World Journal of Gastrointestinal Pharmacology and Therapeutics · 7

Comparative analysis of inflammatory bowel disease (IBD) patient- and service-reported quality of care using 2019 and 2023 UK benchmarking data from more than 26 000 adult patient respondents and 154 IBD services

2026 · A Barney Hawthorne, Paul Christiansen, et al. · Journal of Crohn s and Colitis · 4

Advanced therapy screening in inflammatory bowel disease and the impact of clinical nurse specialists: A retrospective analysis of electronic patient records

2025 · Michael Colwill, Arin Ward, et al. · Clinical Medicine · 1

P1095 Switching from Ustekinumab to Risankizumab Improves Outcomes in Crohn’s Disease: A Single-Centre Real-World Data Analysis

2025 · U Qazi, J Padley, et al. · Journal of Crohn s and Colitis · 1

Real‐World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group

2026 · David Young, Cheryl Booker, et al. · Alimentary Pharmacology & Therapeutics

P96 Advanced therapy screening: IBD clinical nurse specialists and it solutions improve adherence to guidelines and quality of care

2024 · Michael Colwill, Kevin Jacob, et al. · Gut

P130 Virtual biologics and immunomodulator clinic (VBIC): a review of activity in a tertiary IBD centre

2023 · Aaron Bhakta, Blessy Thomas, et al. · Gut

P93 Positioning tofacitinib first line for moderate to severe ulcerative colitis: impact on effectiveness of subsequent treatments

2023 · Alexandra Agorogianni, Richard Hall, et al. · Gut

P498 Ustekinumab Real World Evidence Study (UndieS): study design with information about positioning and the choice of ustekinumab

2023 · D Young, C Booker, et al. · Journal of Crohn s and Colitis

Works count: 11

Citation count: 178

H-index: 4

I10-index: 2